CN117098780A - 单域pd-l1抗体 - Google Patents

单域pd-l1抗体 Download PDF

Info

Publication number
CN117098780A
CN117098780A CN202280021890.7A CN202280021890A CN117098780A CN 117098780 A CN117098780 A CN 117098780A CN 202280021890 A CN202280021890 A CN 202280021890A CN 117098780 A CN117098780 A CN 117098780A
Authority
CN
China
Prior art keywords
ser
gly
val
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280021890.7A
Other languages
English (en)
Chinese (zh)
Inventor
蒋雯卿
刘岩
顾海娟
崔菲菲
王正毅
郭炳诗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjing Biotechnology Shanghai Co ltd
Original Assignee
Tianjing Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjing Biotechnology Shanghai Co ltd filed Critical Tianjing Biotechnology Shanghai Co ltd
Publication of CN117098780A publication Critical patent/CN117098780A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280021890.7A 2021-04-26 2022-04-26 单域pd-l1抗体 Pending CN117098780A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021090058 2021-04-26
CNPCT/CN2021/090058 2021-04-26
CN2021090046 2021-04-26
CNPCT/CN2021/090049 2021-04-26
CNPCT/CN2021/090046 2021-04-26
CN2021090049 2021-04-26
PCT/CN2022/089388 WO2022228445A1 (en) 2021-04-26 2022-04-26 Single domain pd-l1 antibodies

Publications (1)

Publication Number Publication Date
CN117098780A true CN117098780A (zh) 2023-11-21

Family

ID=83847760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280021890.7A Pending CN117098780A (zh) 2021-04-26 2022-04-26 单域pd-l1抗体

Country Status (5)

Country Link
US (1) US20240209093A1 (https=)
EP (1) EP4330287A4 (https=)
JP (1) JP2024514277A (https=)
CN (1) CN117098780A (https=)
WO (1) WO2022228445A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies
WO2024261338A1 (en) * 2023-06-22 2024-12-26 Ablynx Nv Immunoglobulin single variable domains targeting pd-l1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
EP3816186A4 (en) * 2018-06-29 2022-04-06 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. PD-L1 BINDING POLYPEPTIDES AND USE THEREOF
TWI793395B (zh) * 2019-01-25 2023-02-21 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
CN112142842B (zh) * 2019-06-27 2023-09-01 启愈生物技术(上海)有限公司 抗PD-L1纳米抗体及其Fc融合蛋白和应用
CN112409483B (zh) * 2019-08-22 2024-08-27 浙江道尔生物科技有限公司 抗pd-l1纳米抗体
CN115947846A (zh) * 2019-09-12 2023-04-11 普米斯生物技术(珠海)有限公司 一种抗pd-l1纳米抗体及其衍生物和用途
CN112574309B (zh) * 2019-12-05 2023-06-16 启愈生物技术(上海)有限公司 一种抗pd-l1纳米抗体及其用途

Also Published As

Publication number Publication date
EP4330287A4 (en) 2025-03-19
EP4330287A1 (en) 2024-03-06
JP2024514277A (ja) 2024-03-29
US20240209093A1 (en) 2024-06-27
WO2022228445A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
US20210363266A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
JP7538131B2 (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
CN117098780A (zh) 单域pd-l1抗体
KR20230079165A (ko) 항-클라우딘18.2 및 cd3 이특이적 항체 및 이의 용도
IL304096A (en) Pd-1 binding molecule and application thereof
KR20230015957A (ko) 이중특이적 항체 및 이의 용도
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN115785268A (zh) 抗cd47抗体及其用途
CN110913894B (zh) 抗csf-1r抗体、其抗原结合片段及其医药用途
KR102939584B1 (ko) 인간 cd47-표적화 단일-도메인 항체 및 그 사용
AU2021411652A1 (en) Mesothelin binding molecule and application thereof
CN116199778B (zh) 抗4-1bb抗体及其用途
CA3209827A1 (en) Anti-tnfr2 antibody and use thereof
WO2024104373A1 (en) Anti-pd-l1 nanobodies
KR102862614B1 (ko) Cd47에 대한 단일 도메인 항체 및 이의 용도
CN121079324A (zh) 抗cntn4抗体及其用途
CN115335402B (zh) 特异性抗原结合分子,其制备方法及医药用途
JP2021534204A (ja) 抗ＳＩＲＰｇ化合物
RU2817143C2 (ru) Антитело против cd79b, его антигенсвязывающий фрагмент и его фармацевтическое применение
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
AU2026201066A1 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN120051489A (zh) 抗cd100抗体及其用途
AU2021362977A1 (en) Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination